ISSN 1662-4009 (online)

ey0018.4-2 | Important for clinical practice | ESPEYB18

4.2. Clinical characteristics of short-stature patients with an NPR2 mutation and the therapeutic response to rhGH

Ke X , Liang H , Miao H , Yang H , Wang L , Gong F , Pan H , Zhu H

Clin Endocrinol Metab. 2021;106(2):431–441. doi: 10.1210/clinem/dgaa842. PMID: 33205215This study aimed to describe the clinical characteristics of 6 patients with NPR2 gene mutations and the response to rhGH treatment in 2 of them.The natriuretic peptide receptor 2 gene (NPR2) is a paracrine factor involved in the regulation of cell proliferati...

ey0018.9-11 | Cancer treatment, growth and growth hormone therapy | ESPEYB18

9.11. Height after photon craniospinal irradiation in pediatric patients treated for central nervous system embryonal tumors

M Mizumoto , Y Oshiro , H Pan , F Wang , SC Kaste , A Gajjar , W Chemaitilly , TE. thomas.merchant@stjude.org Merchant

Pediatr Blood Cancer. 2020; 67: e28617. https://pubmed.ncbi.nlm.nih.gov/32715632/This retrospective single-centre study aimed to develop a final height prediction model based on data from 212 long-term survivors (aged 5-20.4 years) of childhood central nervous system (CNS) tumors who received craniospinal irradiation (CSI) and with a median follow up of 10.2 years. Mean fin...

ey0021.13-6 | Endocrinology | ESPEYB21

13.6. Identification of southern Taiwan genetic variants in thyroid dyshormonogenesis through whole-exome sequencing

CC Tsai , YM Chang , YY Chou , SY Chen , YW Pan , MC Tsai

Brief Summary: This cohort study identified genetic variants associated with thyroid dyshormonogenesis as a cause of congenital hypothyroidism in Southern Taiwan. It reviewed 876 CH patients diagnosed between 2011 and 2022 and examined the genetic etiology in 47 cases of TDH using whole-exome sequencing (WES).The etiology of congenital hypothyroidism (CH) can be attributed to either thyroid dysgenesis (TD) or thyroid dyshormonogenesis (TDH) with TD usual...

ey0016.13-15 | Growth and Nutrition | ESPEYB16

13.15. The obesity transition: stages of the global epidemic

LM Jaacks , S Vandevijvere , A Pan , CJ McGowan , C Wallace , F Imamura , D Mozaffarian , B Swinburn , M Ezzati

Lancet Diabetes Endocrinol 2019; 7: 231–40. DOI: 10.1016/S2213-587(19)30026-9• This study uses quantitative data from reputable global data sets to demonstrate that the epidemiology of obesity can be framed as a conceptual model of obesity transition.• A new framework to classify the obesity epidemic is proposed that may assist policy makers and r...

ey0020.11-9 | Diabetes | ESPEYB20

11.9. Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019

J Xie , M Wang , Z Long , H Ning , J Li , Y Cao , Y Liao , G Liu , F Wang , A Pan

Brief summary: The authors used data from the Global Burden of Disease 2019 to examine the incidence, disability adjusted life years and mortality of early onset type 2 diabetes T2D) in those 15–39 years of age. This showed that early onset T2D is a growing global health problem in adolescents and young adults, particularly in low-middle- and middle-income countries.Early onset of type 2 diabetes (T2D) is associated with longer lifetime exposure hyp...

ey0016.12-2 | Type 2 Diabetes | ESPEYB16

12.2. Risk of type 2 diabetes in adolescents and young adults with attention-deficit/hyperactivity disorder: a nationwide longitudinal study

MH Chen , TL Pan , JW Hsu , KL Huang , TP Su , CT Li , WC Lin , SJ Tsai , WH Chang , TJ Chen , YM Bai

J Clin Psychiatry 2018;79.DOI: 10.4088/JCP.17m11607Summary: In a population-based prospective cohort study, based on the Taiwan National Health Insurance Research Database, 35,949 adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD) had a higher risk of developing T2DM and had a shorter duration between enrollment and onset of T2DM ...

ey0018.11-4 | New hope: Increased diagnostic yield for disease causing MC4R variants and pharmacological treatment options | ESPEYB18

11.4. Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort

KH Wade , BYH Lam , A Melvin , W Pan , LJ Corbin , DA Hughes , K Rainbow , JH Chen , K Duckett , X Liu , J Mokrosiński , A Morseburg , S Neaves , A Williamson , C Zhang , IS Farooqi , GSH Yeo , NJ Timpson , S O'Rahilly

Nat Med, 2021 Jun;27(6):1088–1096. 10.1038/s41591-021-01349-y. https://pubmed.ncbi.nlm.nih.gov/34045736/This paper reports the high prevalence of MC4R loss-of-function (LoF) variants in a normal population and their large impact on longitudinally assessed anthropometric traits from birth to young adult life.Th...

ey0019.14-3 | Basics of human biology | ESPEYB19

14.3. Structure and transport mechanism of the human cholesterol transporter ABCG1

Xu Da , Li Yanyan , Yang Fengrui , Sun Cai-Rong , Pan Jinheng , Wang Liang , Chen Zhi-Peng , Fang Shu-Cheng , Yao Xuebiao , Hou Wen-Tao , Zhou Cong-Zhao , Chen Yuxing

Cell Rep. 2022 Jan 25;38(4):110298. doi: 10.1016/j.celrep.2022.110298Brief Summary: This study describes the cryo-EM structure of human ATP Binding Cassette Subfamily G Member 1 (ABCG1) in complex with cholesterol. The authors propose a structural mechanism whereby cholesterol is recruited from cell membranes by sphingomyelin and loaded on nascent HDL particles.ABC...

ey0019.15-17 | Basic Science and Genetics | ESPEYB19

15.17. Sex-specific genetic regulation of adipose mitochondria and metabolic syndrome by Ndufv2

Krishnan K Chella , L Vergnes , R Acin-Perez , L Stiles , M Shum , L Ma , E Mouisel , C Pan , TM Moore , M Peterfy , CE Romanoski , K Reue , JLM Bjorkegren , M Laakso , M Liesa , AJ Lusis

Nat Metab. 2021;3(11):1552-68. doi: 10.1038/s42255-021-00481-w.PubMed ID: 34697471Brief summary: This study identified a genetic locus on mouse chromosome 17, containing the gene Ndufv2, that controls mitochondrial mass and function in adipose tissue in a sex- and tissue-specific manner. In female mice, Ndufv2 regulated the expression of 89 mitochondrial genes, with invol...

ey0020.3-1 | Novel Treatments for Rare Skeletal Disorders | ESPEYB20

3.1. Safety and efficacy of denosumab for fibrous dysplasia of bone

LF de Castro , Z Michel , K Pan , J Taylor , V Szymczuk , S Paravastu , B Saboury , GZ Papadakis , X Li , K Milligan , B Boyce , SM Paul , MT Collins , AM Boyce

In Brief: This phase 2 study investigated the effect of the RANKL inhibitor denosumab on fibrous dysplasia lesion activity, as well as the rebound in bone turnover after treatment discontinuation.Commentary: Denosumab is a humanized monoclonal antibody that inhibits RANKL with potent but transient antiosteoclastic effects, and discontinuation of denosumab treatment is associated with a rebound in bone turnover. In this study, eight women received high do...